GlobeNewswire
-
XORTX Patent Allowed for XRx-101 Program by Japan Patent Office
13/11/2026 -
FREHEMGO® (denecimig) approved in the EU for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing
13/11/2026 -
RAMSAY GENERALE DE SANTE : COMBINED GENERAL MEETING OF DECEMBER 4, 2026
13/11/2026 -
RAMSAY GENERALE DE SANTE : ASSEMBLEE GENERALE MIXTE DU 4 DECEMBRE 2026
13/11/2026 -
CUKTECH Makes MPL Malaysia S18 Playoffs Debut to Champion Reliable Power and Peak Performance in Esports
13/11/2026 -
Zealand Pharma announces EU approval of Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
13/11/2026 -
COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering
13/11/2026 -
Sol y Vida Recognizes National Diabetes Awareness Month, Honoring the Families and Communities Leading the Way on Early Detection
13/11/2026 -
Lifeward Reports Third Quarter 2026 Financial Results and Provides Business Update
13/11/2026 -
UPDATED -- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update
13/11/2026 -
Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
13/11/2026 -
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
13/11/2026 -
NeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach
13/11/2026 -
Cannabix Technologies to Present Multi-Drug Breath Technology at BC Centre for Excellence on Substance Use Disorders
13/11/2026 -
Sienna Announces November Dividend
13/11/2026 -
Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026
13/11/2026 -
Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026
13/11/2026 -
Kyntra Bio to Report Third Quarter 2026 Financial Results
13/11/2026 -
AIM ImmunoTech Approaches Major Clinical Inflection Point with Phase 2 Pancreatic Cancer Data Expected Q1 2027; Reports Third Quarter 2026 Financial Results
13/11/2026
Pages